Amicus Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Amicus Therapeutics (FOLD) Misses Q3 EPS by 56c, Revenues Miss; Offers FY18 Revenue Outlook Below Consensus
November 5, 2018 7:05 AM ESTAmicus Therapeutics (NASDAQ: FOLD) reported Q3 EPS of ($0.84), $0.56 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $20.6 million versus the consensus estimate of $23.57 million.
John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc. stated, The third... More
